|
|
|
Volumn 2, Issue 10, 2001, Pages 1423-1427
|
|
SR-121463 Sanofi-Synthélabo
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE;
CONIVAPTAN;
MOZAVAPTAN;
N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE;
RELCOVAPTAN;
VASOPRESSIN V2 RECEPTOR;
BINDING AFFINITY;
CLINICAL TRIAL;
CONGESTIVE HEART FAILURE;
DRUG BINDING;
DRUG ELIMINATION;
DRUG INDICATION;
DRUG MECHANISM;
DRUG METABOLISM;
DRUG POTENCY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
GLAUCOMA;
HUMAN;
HYPERTENSION;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
REVIEW;
STRUCTURE ACTIVITY RELATION;
ANIMALS;
ANTIHYPERTENSIVE AGENTS;
GLAUCOMA;
HEART FAILURE, CONGESTIVE;
HUMANS;
HYPERTENSION;
MORPHOLINES;
RECEPTORS, VASOPRESSIN;
SPIRO COMPOUNDS;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
|
EID: 0034777171
PISSN: 09678298
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (2)
|
|
References (28)
|
